GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Short-term investments

Aclaris Therapeutics (FRA:8AT) Short-term investments


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.


Aclaris Therapeutics Business Description

Traded in Other Exchanges
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.